-
Leupeptin: Protease Workflow and Troubleshooting
2026-09-20
Build reproducible protease inhibition, protein degradation, autophagy, and viral replication workflows with fresh Leupeptin hemisulfate salt. This guide pairs target-specific kinetic controls with the binding-validation logic of a modern TET2 protocol, while clearly separating established evidence from practical extensions.
-
Ferroptosis Signature Identifies Atorvastatin in HCC
2026-09-19
Wang and colleagues combined ferroptosis-related transcriptomics, survival modeling, and Connectivity Map screening to develop a four-gene prognostic signature for hepatocellular carcinoma and identify Atorvastatin as a candidate therapeutic compound. Their in vitro and in vivo results support further investigation of ferroptosis-oriented HCC treatment, while remaining preclinical rather than clinical evidence.
-
Ko 143: A Practical BCRP Inhibitor Workflow
2026-09-18
Ko 143 provides a selective way to test whether BCRP-driven efflux is limiting intracellular drug exposure, chemotherapy response, or systemic pharmacokinetics. This workflow combines cell-based resistance assays, transporter controls, LC-MS/MS, and in vivo study design to distinguish BCRP effects from broader MDR mechanisms.
-
Live-Cell Mapping of Glycan–GBP Interactions
2026-09-18
Joeh and colleagues introduced a live-cell proximity-tagging workflow that converts weak, transient glycan–glycan-binding protein interactions into covalently labeled protein populations suitable for imaging and quantitative proteomics. By combining a peroxidase–galectin-3 fusion with biotin-phenol labeling, streptavidin enrichment, and mass spectrometry, the method maps glycoprotein counter-receptors while preserving the cellular context.
-
Tariquidar and the Mechanics of Chemoresistance
2026-09-17
High extracellular viscosity can activate a mechanobiology-to-P-glycoprotein axis that strengthens chemoresistance. This article explains how Tariquidar (XR9576) can help translational researchers distinguish transporter-mediated drug efflux from broader microenvironmental effects, while outlining controls for ABC transporter inhibition, assay interpretation, and future cancer chemoresistance studies.
-
1,2-Dioleoyl-3-trimethylammonium-propane chloride
2026-09-17
A scenario-based guide to using 1,2-Dioleoyl-3-trimethylammonium-propane chloride (DOTAP, SKU C4876) in transfection, viability, proliferation, and cytotoxicity workflows. It explains how to separate carrier effects from nucleic-acid activity, optimize lipid–cargo complexation, and evaluate supplier reliability without overstating evidence.
-
Taltirelin Improves Motor Function Without Dyskinesia
2026-09-16
The reference study shows that the long-acting TRH analog Taltirelin improves motor deficits in 6-hydroxydopamine-lesioned hemi-Parkinsonian rats without producing dyskinesia during short-term treatment. Its sustained, moderate dopamine-releasing effect, involving VMAT2, DAT, TH, and p-ERK1/2 signaling, provides a mechanistic rationale for further preclinical Parkinson’s disease research.
-
2-D08 (2’,3’,4’-trihydroxyflavone) in Cell Assays
2026-09-16
A scenario-driven guide to using 2-D08 (2’,3’,4’-trihydroxyflavone), SKU C4445, in cell viability, proliferation, and cytotoxicity workflows. It explains mechanism, formulation, protocol controls, data interpretation, and practical product-selection criteria without overstating preclinical evidence.
-
Intraarticular Resiniferatoxin for Osteoarthritis Pain
2026-09-15
The 2025 review evaluates resiniferatoxin (RTX) as a localized TRPV1-directed intervention for osteoarthritic pain, integrating mechanistic, animal, canine, and early human evidence. Its central contribution is to frame intra-articular RTX as a potential long-duration analgesic strategy based on selective chemical silencing of TRPV1-positive nociceptive terminals, while also emphasizing dose, volume, safety, and translational uncertainties.
-
Homoharringtonine: From Ribosome to Translation
2026-09-15
A translational perspective on Homoharringtonine, connecting ribosome-directed cytotoxicity, leukemia research, and emerging SARS-CoV-2 antiviral research while outlining evidence standards, assay design, formulation considerations, and strategic next steps.
-
Resiniferatoxin: Context-Aware TRPV1 Assays
2026-09-14
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist whose effects depend on exposure, tissue compartment, and disease context. This guide develops an assay framework that separates neuronal desensitization from immune modulation for more rigorous pain and translational studies.
-
Rotenone Workflows for Mitochondrial Stress Research
2026-09-14
Use Rotenone as a controlled mitochondrial Complex I inhibitor to connect energy failure, mitochondrial ROS, and regulated cell death in cardiomyocyte and neuronal models. This practical workflow emphasizes dose finding, orthogonal readouts, and a literature-grounded strategy for testing whether NLRP3 signaling depends on mitochondrial stress.
-
Maternal Deltamethrin Exposure, Ferroptosis, and Memory
2026-09-13
The reference study links maternal deltamethrin exposure with impaired hippocampal learning and memory in male offspring through a p53-associated ferroptosis pathway. Its combination of developmental exposure, behavioral testing, hippocampal pathology, biochemical profiling, and HT-22 cell experiments provides a useful framework for studying how environmental toxicants connect p53 signaling, redox failure, and calcium homeostasis.
-
EdU Cell Proliferation Kit: Signal to Decision
2026-09-12
The EdU Cell Proliferation Kit (TMB) converts nascent DNA synthesis into a practical S-phase readout for mechanistic and translational studies. This guide explains how to interpret EdU signals in ARL4C-driven rheumatoid arthritis research without confusing proliferation with invasion, apoptosis, or macrophage polarization.
-
Biomimetic mRNA Nanovaccines Target Neutrophils
2026-09-11
A 2026 study developed CD300LD-targeted, cell-membrane-coated liposomes carrying mRNA encoding albumin-fused IL-36γ to activate tumor-associated neutrophils in hepatocellular carcinoma. The approach reframes neutrophils as therapeutically reprogrammable immune effectors and provides a rationale for combining receptor-guided delivery with cytokine mRNA engineering.